{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:09:11Z","timestamp":1779923351938,"version":"3.53.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>\n                    <jats:bold>The US Food and Drug Administration has recently approved a number of new direct\u2010acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug\u2010drug interactions. These interactions must be considered both when starting and stopping any medication, including over\u2010the\u2010counter medications and herbal supplements. These drug\u2010drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug\u2010drug interactions for direct\u2010acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions<\/jats:bold>\n                    . (H\n                    <jats:sc>epatology<\/jats:sc>\n                    2016;63:634\u2013643)\n                  <\/jats:p>","DOI":"10.1002\/hep.27920","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T12:55:23Z","timestamp":1432904123000},"page":"634-643","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["A clinician's guide to drug\u2010drug interactions with direct\u2010acting antiviral agents for the treatment of hepatitis C viral infection"],"prefix":"10.1097","volume":"63","author":[{"given":"Travis B.","family":"Dick","sequence":"first","affiliation":[{"name":"Department of,Pharmacy Intermountain Medical Center,Murray,UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance S.","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Department of,Pharmacy Intermountain Medical Center,Murray,UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra D.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Department of,Pharmacy Intermountain Medical Center,Murray,UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Charlton","sequence":"additional","affiliation":[{"name":"Department of Transplantation,Intermountain Medical Center,Murray,UT."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,9,21]]},"reference":[{"key":"hep27920-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic\u2010pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"hep27920-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2174\/138945011795378504","article-title":"ABC multidrug transporters: target for modulation of drug pharmacokinetics in drug\u2010drug interactions","volume":"12","year":"2011","journal-title":"Curr Drug Targets"},{"key":"hep27920-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient: part IV: drug\u2010drug interactions","volume":"111","year":"2005","journal-title":"Circulation"},{"key":"hep27920-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir\u2010boosted atazanavir, efavirenz, and tenofovir","volume":"18","year":"2013","journal-title":"Antiviral Ther"},{"key":"hep27920-bib-0012-20241017","first-page":"374","article-title":"Interferon activation and innate immunity","volume":"2","year":"2000","journal-title":"Rev Immunogenet"},{"key":"hep27920-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007890-199907270-00027","article-title":"Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels","volume":"68","year":"1999","journal-title":"Transplantation"},{"key":"hep27920-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/lt.20165","article-title":"Management of drug\u2010to\u2010drug interactions between cyclosporine A and the protease\u2010inhibitor lopinavir\/ritonavir in liver\u2010transplanted HIV\u2010infected patients","volume":"10","year":"2004","journal-title":"Liver Transpl"},{"key":"hep27920-bib-0015-20241017","first-page":"2375","article-title":"An interferon\u2010free antiviral regimen for HCV after liver transplantation","volume":"317","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27920-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/TP.0b013e3182734651","article-title":"Pretransplantation pharmacokinetic curves of tacrolimus in HIV\u2010infected patients on ritonavir\u2010containing cART: a pilot study","volume":"95","year":"2013","journal-title":"Transplantation"},{"key":"hep27920-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","year":"2008","journal-title":"J Hepatol"},{"key":"hep27920-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"hep27920-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep27920-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/17512433.2014.910111","article-title":"Understanding and preventing drug\u2010drug and drug\u2010gene interactions","volume":"7","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"hep27920-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/0091270006287704","article-title":"Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects","volume":"46","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 1","key":"hep27920-bib-0027-20241017","first-page":"1000A","article-title":"The pharmacokinetic interaction between the investigational NS3\u20104A HCV protease inhibitor TMC435 and methadone [Abstract]","volume":"54","year":"2011","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27920","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201602000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T19:33:58Z","timestamp":1729193638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201602000-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,21]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27920","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725529295.793507268","asserted-by":"object"}]},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,21]]},"assertion":[{"value":"2015-03-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}